The immunotherapy using LCN2 neutralization may be a promising clinical approach to treat and prevent neuropathology in dementia, suggesting that LCN2 deficiency markedly suppresses neuroinflammation based on preclinical studies for various CNS disorders,172 such as traumatic brain damage,173 experimental autoimmune encephalomyelitis,174 and stroke.175. The gene discussed is LCN2; the disease is experimental autoimmune encephalomyelitis.